ArticleHeliyon2025
From dyspnea to Olympic qualification - A case report as a model for post-acute sequelae of COVID-19.
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pulmonary post-acute COVID-19 sequelae (PASC) can occur in professional athletes. In these individuals, the physical impairment can ultimately mean the end of their career due to the lack of specific treatment strategies. Individualised treatment approaches are required, as demonstrated in this case report. Case presentation: Using the example of a female professional athlete, an individualised therapy strategy is outlined step by step on the basis of the assessment of lung function, including spiroergometry, CT imaging and immunocytological and histopathological analysis of bronchoscopically obtained material. This multimodal diagnostic approach was used to identify persistent inflammation without viral persistence and to create an individual treatment plan. In addition to the use of azithromycin and anti-obstructive inhalation therapy, the patient also received three sessions of thermoplasty and a new approach to physiotherapy (myoreflex therapy). This gradually freed the athlete from her restrictions. Over time, she was able to regain her athletic performance, which ultimately led to her successful qualification for the 2024 Summer Olympics in Paris. All objective examination parameters indicated a remission of pulmonary PASC. Discussion: To date, there are no clear treatment recommendations for PASC. The most commonly prescribed treatment regimens often fail to achieve objective success. The present case highlights the need for an individualised diagnostic and therapeutic approach and that complete remission of PASC can be achieved. Based on our findings, multidisciplinary phenotyping of individual cases of pulmonary PASC appears to be of central importance as a basis for an individualised therapeutic approach. It should also be emphasised that the inflammatory processes persist without viral persistence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.